Abstracts Archive - Page 843 of 2425 - ACR Meeting Abstracts

Abstract Number: 1269 • 2019 ACR/ARP Annual Meeting
Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Jing Chen ¹, Yi Luo ¹, Mengzhu Zhao ¹, Di Wu ¹, Yunjiao Yang ², Wen Zhang ³ and Min Shen¹, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)
Background/Purpose: Blau syndrome (BS) is a rare dominantly inherited autoinflammatory disorder associated with mutations in the NOD2 gene. BS is mainly seen in Caucasian patients.…
Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting
Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Martin Michaud¹, Thomas Sene ², Pascal Chazerain ², Geoffrey Urbanski ³, Frederique Retornaz ⁴, Boris Bienvenu ⁵, Laurent Chiche ⁴, Florian Catros ⁶, Laurent Sailler ⁷, Laurent Alric ⁸, Jean Thomas Giraud ⁹, Léo Caudrelier ¹⁰, Slim Lassoued ¹⁰, Sophie Ancellin ⁶, Olivier Lidove ² and Francis Gaches ⁶, ¹Joseph Ducuing Hospital, Toulouse, France, ²Hôpital Croix Saint Simon, Paris, France, ³CHU Angers, Angers, France, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Saint Joseph, Marseille, France, ⁶Hôpital Joseph Ducuing, Toulouse, France, ⁷University Hospital of Toulouse, Toulouse, France, ⁸CHU Toulouse, Toulouse, France, ⁹Hôpital de Tarbes, Tarbes, France, ¹⁰Hôpital de Cahors, Cahors, France
Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
Abstract Number: 1271 • 2019 ACR/ARP Annual Meeting
Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment
Ivette Casafont-Solé¹, Susana Holgado ¹, Javier Narváez ², Maribel Mora ³, Josep Roca ⁴, Anahy Brandy-Garcia ¹, Lourdes Mateo ¹, Melania Martínez-Morillo ¹, Laia Gifre ¹, Maria Aparicio-Espinar ¹, Águeda Prior-Español ¹, Anne Riveros-Frutos ¹, Clara Sangüesa ¹, Jordi Camins-Fàbregas ¹, Annika Nack ¹, Joan Miquel Nolla ³ and Alejandro Olivé-Marqués ⁴, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
Background/Purpose: Adult-onset Still’s disease (AOSD) is a low prevalent disease with an unpredictable clinical course and variable prognosis. Sometimes, it requires biologic treatment in early…
Abstract Number: 1272 • 2019 ACR/ARP Annual Meeting
Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study
DIANA PRIETO- PENA¹, Vanesa Calvo Río ², Mónica Calderón-Goercke ³, Olga Maíz Alonso ⁴, A Blanco ⁵, Javier Narváez ⁶, Santos Castañeda ⁷, E Vicente ⁸, Susana Romero-Yuste ⁹, Rosalia Demetrio ¹⁰, Ana Urriticoechea Arana ¹¹, JL García Serrano ¹², JL Callejas Rubio ¹², Norberto Ortego Centeno ¹², Julio Sanchez ¹³, Lucia Cristina Dominguez Casas ¹⁰, Lara Sanchez-Bilbao ², Iñigo Gonzalez-Mazon ¹, Miguel Angel González-Gay ¹⁴ and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴H. Donostia, San Sebastián, Spain, ⁵H. Donostia, Donostia, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁷Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁸H. Princesa, Madrid, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹¹H. Can Misses, Ibiza, Spain, ¹²H. San Cecilio, Granada, Spain, ¹³H. 12 de Octubre, Madrid, Spain, ¹⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Non ischaemic optic neuritis (NION) is a severe inflammation of the optic nerve that may lead to blindness. It can be primary or associated…
Abstract Number: 1273 • 2019 ACR/ARP Annual Meeting
Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study
DIANA PRIETO- PENA¹, Vanesa Calvo Río ², Mónica Calderón-Goercke ³, Olga Maíz Alonso ⁴, JR Jimenez-Aberasturi ⁵, Raul Veroz ⁶, Maria Soledad Blanco ⁷, José Manuel Santos ⁸, Francisco Navarro ⁹, Adela Gallego ¹⁰, Rosalia Demetrio ¹¹, Victor Manuel Martínez Taboada ¹¹, Miguel Angel González-Gay ¹² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴H. Donostia, San Sebastián, Spain, ⁵HU Araba, Vitoria, Spain, ⁶H. Mérida, Merida, Spain, ⁷H. Galdakano, Bilbao, Spain, ⁸H. Río Hortega, Valladolid, Spain, ⁹H.Elche, Alicante, Spain, ¹⁰H. Badajoz, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Uveitis often occur in women who are in their reproductive years. The management of uveitis during pregnancy is a challenge, making the physician to…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 1275 • 2019 ACR/ARP Annual Meeting
Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
Ana Valle¹, Galina Marder ¹, Maria-Louise Barilla-Labarca ¹ and Sonali Narain ², ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Northwell Health, Great Neck, Long Island, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases with systemic features and multiple comorbidities. Of the myositis associated antibodies seen in this population, anti-SSA/SSB…
Abstract Number: 1276 • 2019 ACR/ARP Annual Meeting
Myositis Specific Antibodies and Clinical Features in Patients from Argentina
Amelia Granel¹, Maria de Los Angeles Gargiulo ², Ana Carolina Marcos ³, Ramiro Gomez ⁴, Andrea Braillard Poccard ⁵, Carolina Costi ⁶, Mercedes Garcia ⁷, Malena Viola ⁸, Maria de la Vega ⁹, Belen Barrios ¹⁰, Silvia Papasidero ¹¹, Boris Kisluk ¹², Guillermo Berbotto ¹², Mariana Aciar ¹³, María Crespo Espíndola ¹⁴, Mariano Rivero ¹⁵, Maria N Lojo ¹⁶, Yessica Ponce Delgado ¹⁷, Oscar Rillo ¹⁸, Ramiro Puerta ¹⁹, Isabel Pineda ²⁰, Dafne Capelusnik ²¹, Roberto Movia ²², Darío Scublinsky ²³, Maria Alicia Lazaro ²⁴ and Graciela Gómez ²⁵, ¹Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, La Plata, Buenos Aires, Argentina, ²Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, ³Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, Gonnet, Argentina, ⁴Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital de Clínicas José de San Martin, Buenos Aires, Buenos Aires, Argentina, ⁶Hospital General “San Martín” de la Plata, La Plata, Buenos Aires, Argentina, ⁷Hospital San Martín, La Plata, Argentina, ⁸Centro Reumatologia DOM, Buenos Aires, Buenos Aires, Argentina, ⁹CEIM Investigaciones Medicas, Buenos Aires, Argentina, ¹⁰Hospital Enrique Tornu,Ciudad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, ¹¹Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹²Hospital Escuela Eva Perón.Granadero Baigorria,Santa Fe.Argentina, Granadero Baigorria, Argentina, ¹³Hospital Ntro Señor del Milagro, Salta.Argentina., Salta, Argentina, ¹⁴Hospital Señor del Milagro, Salta, Salta, Argentina, ¹⁵Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁶Hospital Rossi,La Plata.Argentina, La Plata, Argentina, ¹⁷Hospital Pirovano.Ciudad de Buenos Aires. Argentina, Ciudad de Buenos Aires, Argentina, ¹⁸Hospital Pirovano, Buenos Aires, ¹⁹Hospital Houssay.Vicente Lopez,Buenos Aires.Argentina., Vicente Lopez, Argentina, ²⁰Consultorios Externos Venado Tuerto.Santa Fe.Argentina., Venado Tuerto, Argentina, ²¹Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²²Hospital Evita.Lanus.Pcia Buenos Aires. Argentina, Lanus, Argentina, ²³Centros Médicos Ambulatorios SMG, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²⁴Consultorio Particular, San Isidro, Argentina, ²⁵Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina., Buenos Aires, Argentina
Background/Purpose: To know the frequency of myositis specific antibodies (MSAs) and myositis associated antibodies( MAAs) and their relation with clinical features in patients with idiopathic…
Abstract Number: 1277 • 2019 ACR/ARP Annual Meeting
Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy
Ana Campar¹ and Carlos Vasconcelos ², ¹Centro Hospitalar do Porto, Porto, Portugal, ²University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) remain a major clinical challenge worldwide. The precise aetiopathogenesis of this chronic and disabling disorder remains elusive which precludes the…
Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Patompong Ungprasert¹, Wisit Cheungpasitporn ², Charat Thongprayoon ³, Karn Wijarnpreecha ⁴ and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²University of Mississippi Medical Center, Jackson, MS, ³Mayo Clinic Rochester, Rochester, MN, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…
Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Alain Sánchez-Rodríguez¹, Citlallyc Josefina Gómez-Ruiz ², Abril Montes-Yanes ² and Gabriel Medrano-Ramírez ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Océane Landon-Cardinal¹, Perrine Guillaume-Jugnot ², Lois Bolko ², Ségolène Toquet ², Aude Rigolet ², Baptiste Hervier ³, Nicolas Champtiaux ², Mathieu VAUTIER ⁴, Olivier Benveniste ⁵ and Yves Allenbach ⁵, ¹Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ²Pitié-Salpêtrière University Hospital, Paris, France, ³Hopital Pitie-Salpetriere, Paris, France, ⁴Paris - Pitié salpétrière, Paris, France, ⁵Sorbonne Université, Paris, France
Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…
Abstract Number: 1281 • 2019 ACR/ARP Annual Meeting
Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?
Tsuneo Sasai¹, Ran Nanashima ¹, Tsuneyo Mimori ², Hideaki Tsuji ¹, Shuji Akizuki ¹, Kosaku Murakami ³, Motomu Hashimoto ³, Hajime Yoshifuji ¹, Masao Tanaka ² and Koichiro Ohmura ², ¹Kyoto University, Kyoto, Japan, ²Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor life prognosis…
Abstract Number: 1282 • 2019 ACR/ARP Annual Meeting
Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis
Prasanth Lingamaneni¹, Carrie Richardson ², Soumyasri Kambhatla ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago
Background/Purpose: Adults with polymyositis demonstrate wide variability in responses to treatment, and the risk factors for failure to achieve remission in polymyositis are largely unknown. …
Abstract Number: 1283 • 2019 ACR/ARP Annual Meeting
Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study
Nantakarn Pongtarakulpanit¹, Khemmapop Yongchairat ², Wanruchada Kachamart ², Charungthai Dejthevaporn ¹, Natta Rajatanavin ¹ and Parawee Chevaisrakul ¹, ¹Ramathibodi hospital, Mahidol University, Bangkok, Thailand, ²Siriraj Hospital, Mahidol university, Bangkok, Thailand
Background/Purpose: The association between idiopathic inflammatory myopathies (IIMs) and malignancies in Thai population has been rarely reported. The objective of our study was to determine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].